Vascular Biogenics Ltd. (VBLT) NASDAQ
0.16
-0.015(-8.77%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
Vascular Biogenics Ltd.
Sector
Healthcare
Industry
Biotechnology
Employees
7
First IPO Date
October 01, 2014
Key Executives
| Name | Title | Pay | Year Born |
| Dror Harats | Chief Executive Officer & Director | 444,333 | 1957 |
| Samuel Backenroth | Chief Financial Officer | 410,000 | 1984 |
| Advocate Ayelet Horn | Gen. Counsel | 0 | 1971 |
| Deborah Scott | Managing Director of Financial Communications | 0 | N/A |
| Erez Feige | Senior Vice President of Bus. Operations | 0 | 1974 |
| Eyal Breitbart | Senior Vice President of Research & Operations | 0 | 1967 |
| Naamit Sher | Senior Vice President of Drug Devel. & Regulatory Affairs | 0 | 1954 |
| Tami Rachmilewitz | Senior Vice President of Clinical Devel. | 0 | 1971 |
| Yael Cohen | Medical Director | 0 | 1963 |
Description
Vascular Biogenics Ltd., a clinical stage biopharmaceutical company, develops therapeutics for the treatment of cancer and immune-inflammatory diseases in Israel and the United States. Its programs are based on its vascular targeting system, a gene-based technology targeting newly formed blood vessels; and monocyte targeting technology, an antibody-based technology that enables specifically inhibit monocyte migration for immune-inflammatory applications. The company's lead product candidate is VB-111, a gene-based biologic that is in Phase III clinical trials for the recurrent platinum-resistant ovarian cancer; and Phase II clinical trials treatment of recurrent glioblastoma and colorectal cancer, as well as has completed Phase II clinical trial for the treatment of thyroid cancer. It is also developing VB-601 for various inflammatory indications, and VB-611 for various solid tumors. The company was formerly known as Medicard Ltd. and changed its name to Vascular Biogenics Ltd. in January 2003. Vascular Biogenics Ltd. was incorporated in 2000 and is headquartered in Modi'in, Israel.
